Shopping Cart
- Remove All
Your shopping cart is currently empty
CIB-L43 is a high affinity and orally available TRBP inhibitor (KD = 4.78 nM), which can effectively inhibit the biosynthesis of oncogenic miR-21, increase the expression of PTEN and Smad7, and block the AKT and TGF-β signaling pathways to inhibit the proliferation and migration of hepatocellular carcinoma (HCC) cells.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $64 | In Stock | |
| 5 mg | $153 | In Stock | |
| 10 mg | $247 | In Stock | |
| 25 mg | $495 | In Stock | |
| 50 mg | $793 | In Stock | |
| 100 mg | $1,190 | In Stock | |
| 200 mg | $1,630 | In Stock |
| Description | CIB-L43 is a high affinity and orally available TRBP inhibitor (KD = 4.78 nM), which can effectively inhibit the biosynthesis of oncogenic miR-21, increase the expression of PTEN and Smad7, and block the AKT and TGF-β signaling pathways to inhibit the proliferation and migration of hepatocellular carcinoma (HCC) cells. |
| Targets&IC50 | miR-21 biosynthesis (HCC cells):0.66 nM (EC50), TRBP-Dicer interaction:2.34 μM |
| In vitro | CIB-L43, a 2-phenylthiazole-5-carboxylic acid derivative, binds TRBP with high affinity (KD = 4.78 nM) and disrupts the TRBP-Dicer interaction (IC₅₀ = 2.34 μM). In hepatocellular carcinoma cells, CIB-L43 suppresses oncogenic miR-21 biosynthesis with nanomolar potency (EC₅₀ = 0.66 nM), upregulates tumor suppressors PTEN and Smad7, inhibits AKT and TGF-β signaling, and significantly reduces cell proliferation and migration[1]. |
| In vivo | In hepatocellular carcinoma mouse models, CIB-L43 showed favorable pharmacokinetics, including an oral bioavailability of 53.9%[1]. |
| Synonyms | CIBL43 |
| Molecular Weight | 304.36 |
| Formula | C15H16N2O3S |
| Cas No. | 1082942-70-8 |
| Smiles | O=C(O)C=1SC(=NC1C)C=2C=CC(=CC2)N3CCOCC3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 5.00 mg/mL (16.43 mM), Sonication and heating are recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.